Matches in SemOpenAlex for { <https://semopenalex.org/work/W609511221> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- W609511221 endingPage "166" @default.
- W609511221 startingPage "156" @default.
- W609511221 abstract "espanolLa terapia antiemetica es un logro de la oncologia. Los citostaticos presentan una alta incidencia de nauseas y vomitos (NVPQ) con serias consecuencias para los pacientes y, en ocasiones, llevan a abandonar tratamientos curativos. En los ultimos anos distintos farmacos se han desarrollado para esta indicacion: setrones y antagonistas NK-1. Estos farmacos y los esteroides son el eje del tratamiento antiemetico con tasas de respuesta completa de 70-80 % en quimioterapia altamente emetogena. Pero varios temas relacionados con NVPQ quedan pendientes de resolver: esquemas para tratamientos de varios dias, nauseas tardias, vomitos refractarios o anticipatorios, individualizacion de la antiemesis al paciente, es decir, personalizacion del tratamiento antiemetico, etc. Los setrones son farmacos fundamentales en el tratamiento de las NVPQ. El ultimo, el palonosetron, para algunos es un farmaco superior a los anteriores por su prolongada vida media y su mecanismo de accion, para otros, no aporta ventajas teniendo en cuenta su coste. Actualmente lo ultimo en NVPQ es una combinacion fija de palonosetron y netupitant (NEPA) que aporta ventajas sobre los esquemas convencionales. Aqui hacemos una revision sobre las NVPQ incidiendo en la comparacion entre los setrones y analizando los datos acerca del NEPA. EnglishAntiemetic therapy is a one of the major achievements of oncology. Chemotherapy-induced nausea and vomiting (CINV) is very common and may have serious consequences for patients, even the abandonment of potentially curative treatments. Setrons and NK-1 -antagonist have been developed in the last years to manage CINV and, in combination with steroids, constitute the backbone of antiemetic therapy. Complete responses for highly emetogenic chemotherapy range from 70 to 80 %, although improvements are still needed: Multi-day schemes, delayed nausea, refractory or anticipated vomiting, patient-customized schemes… The last setron to be incorporated was palonosetron. It may be better than other setrons because of its prolonged half-life and mechanism of action, although its superiority has been challenged because of cost. The combination of palonosetron and a new NK-1 -antagonist, netupitant (NEPA) has recently been presented as the ultimate therapy for CINV, with some advantages over conventional schemes. We hereby review therapy for CINV, including a comparison of setrons and recent evidence about NEPA." @default.
- W609511221 created "2016-06-24" @default.
- W609511221 creator A5027996135 @default.
- W609511221 creator A5039997400 @default.
- W609511221 creator A5058175617 @default.
- W609511221 date "2014-01-01" @default.
- W609511221 modified "2023-09-23" @default.
- W609511221 title "Emesis y quimioterapia: papel de los setrones" @default.
- W609511221 hasPublicationYear "2014" @default.
- W609511221 type Work @default.
- W609511221 sameAs 609511221 @default.
- W609511221 citedByCount "0" @default.
- W609511221 crossrefType "journal-article" @default.
- W609511221 hasAuthorship W609511221A5027996135 @default.
- W609511221 hasAuthorship W609511221A5039997400 @default.
- W609511221 hasAuthorship W609511221A5058175617 @default.
- W609511221 hasConcept C138885662 @default.
- W609511221 hasConcept C141071460 @default.
- W609511221 hasConcept C15708023 @default.
- W609511221 hasConcept C2776712918 @default.
- W609511221 hasConcept C2780852908 @default.
- W609511221 hasConcept C2780884295 @default.
- W609511221 hasConcept C71924100 @default.
- W609511221 hasConceptScore W609511221C138885662 @default.
- W609511221 hasConceptScore W609511221C141071460 @default.
- W609511221 hasConceptScore W609511221C15708023 @default.
- W609511221 hasConceptScore W609511221C2776712918 @default.
- W609511221 hasConceptScore W609511221C2780852908 @default.
- W609511221 hasConceptScore W609511221C2780884295 @default.
- W609511221 hasConceptScore W609511221C71924100 @default.
- W609511221 hasIssue "4" @default.
- W609511221 hasLocation W6095112211 @default.
- W609511221 hasOpenAccess W609511221 @default.
- W609511221 hasPrimaryLocation W6095112211 @default.
- W609511221 hasVolume "28" @default.
- W609511221 isParatext "false" @default.
- W609511221 isRetracted "false" @default.
- W609511221 magId "609511221" @default.
- W609511221 workType "article" @default.